Cell Therapy · us
Can Borrowed Immunity Stop a Deadly Brain Infection? Off-the-Shelf T Cells Show Responses in Phase 2 Trial
For progressive multifocal leukoencephalopathy, which currently has no approved therapy, donor-derived, virus-specific T cells that can be frozen in advance and kept ready for use produced rapid and durable responses in a 37-person trial; however, the small, single-arm study is still insufficient to establish efficacy and safety.
The most challenging aspect of progressive multifocal leukoencephalopathy (PML) is that it often strikes people whose immune systems are already severely weakened, and there is still no approved targeted therapy. MD Anderson Cancer Center reported a phase 2 study using virus-specific T cells from healthy donors to restore the immune defenses patients lack. An overall response was observed in 56.8% of the 37 participants, providing an initial clinical signal for this rare and often fatal brain infection.
PML is caused by reactivation of the JC virus, which lies dormant in the human body. The virus attacks the brain’s white matter, causing deterioration in cognition, language, vision, limb strength, and balance. People with hematologic malignancies, AIDS, organ transplants, or autoimmune diseases, as well as those receiving immunosuppressive therapy or cell therapy, are at higher risk. Of the 37 people in the study, 23 had hematologic malignancies; the study also included patients who had received CAR-T-cell therapy or transplantation, as well as patients with impaired immune function due to other diseases.
The therapy does not involve manufacturing new cells for each patient. The research team first collected and expanded T cells from healthy donors that can recognize BK virus, then created a frozen cell bank. Because BK virus and JC virus share some similar features, these cells may also recognize and attack cells infected with JC virus. Compared with personalized cell products that require several weeks to prepare, this “off-the-shelf” design can shorten waiting time when the disease is rapidly worsening.
Trial results showed that 43.2% of patients achieved complete viral clearance, with neurological symptoms stabilizing or improving at the same time; the typical time to response was approximately 23 days. The one-year survival rate for all participants was 61.1%, while the one-year survival rate among those who responded after the first infusion reached 93.3%. The research team also reported that responders had no PML recurrence during follow-up. Lower JC viral load before treatment and greater human leukocyte antigen compatibility between donor and patient were also associated with better responses and survival.
The trial registration information provides additional details on the treatment process: the cells were infused intravenously over 30 minutes. Participants who did not achieve a complete response and remained eligible could receive treatment again after an interval of at least two weeks, followed by regular monitoring for 12 months after completion. The study’s primary objectives covered efficacy, feasibility, and safety, and it also assessed how long the infused T cells could persist in patients’ bodies.
These figures still need to be interpreted cautiously. The study included only 37 people and had no randomization or control group, while the causes of immunosuppression and underlying diseases also varied among patients. Those who responded after the first infusion may already have had a better prognosis, so the 93.3% survival rate cannot be directly regarded as an effect caused by the treatment. The publicly available abstract also does not fully present adverse events, the effects of repeated infusions, or subgroup results for different patient populations, leaving insufficient evidence to determine the precise magnitude of benefits and risks.
Nevertheless, the study advances observations from a small number of early cases into more substantial phase 2 evidence and also indicates that treatment timing and immune compatibility may be critical to success or failure. The trial is still ongoing. Only if subsequent studies reproduce the results with more complete safety data, external or prospective controls, and longer follow-up might off-the-shelf virus-specific T cells gradually move from a rescue option in rare cases toward a standardized treatment for PML.